

## **TMAP Project Management Team Directors**

<http://www.mhmr.state.tx.us/centraloffice/medicaldirector/TMAPover.html>

### **And their ties to the Pharmaceutical Industry**

According to the *New York Times*, Feb 1, 2003, by Melody Petersen, TMAP director Steven Shon reports that TMAP received in excess of six million dollars to develop and expand its program. The bulk of this funding came from the Pharmaceutical industry in the form of grants from the Robert Wood Johnson Foundation, Janssen Pharmaceutica, Johnson & Johnson, Eli Lilly, and Austrazeneca Pfizer, Novartis, Janssen-Ortho-McNeil, GlaxoSmithKline, Abbott, Bristol Myers Squibb, Wyeth-Ayerst Forrest Laboratories and U.S. Pharmacopeia.

- **A. John Rush, M.D.**, The University of Texas Southwestern Medical Center - Dallas: **Project Director**

<http://www.wpic.pitt.edu/STANLEY/4thbipconf/introduction.htm>

#### **A. John Rush, M.D.**

Grant/Research Support

Abbott Laboratories  
Bristol-Myers Squibb Company  
Cyberonics, Inc.  
Forest Pharmaceuticals/Parke Davis  
Glaxo-Wellcome Pharmaceuticals  
Janssen Pharmaceutica  
Robert Wood Johnson Foundation  
Eli Lilly and Company  
Meadows Foundation  
National Institute of Mental Health  
Novartis  
Organon, Inc.  
Pfizer, Inc.  
Pharmacia & Upjohn  
SmithKline Beecham  
Pharmaceuticals  
Stanley Foundation  
Wyeth Ayerst Laboratories  
Zeneca

Consultant

Bristol-Myers Squibb Company  
Cyberonics, Inc.  
Forest Pharmaceuticals/Parke Davis  
Glaxo-Wellcome Pharmaceuticals  
Janssen Pharmaceutica  
Eli Lilly and Company  
Merck & Company, Inc.

Mitsubishi Pharmaceuticals  
National Institute of Mental Health  
Organon, Inc.  
Pfizer, Inc.  
Pharmacia & Upjohn  
Stanley Foundation  
Wyeth Ayerst Laboratories  
Yamanouchi, Inc.

Speakers' Bureau

Abbott Laboratories  
Bristol-Myers Squibb Company  
Cyberonics, Inc.  
Forest Pharmaceuticals/Parke Davis  
Glaxo-Wellcome Pharmaceuticals  
Eli Lilly and Company  
Organon, Inc.  
Pfizer, Inc.  
Pharmacia & Upjohn  
Wyeth Ayerst Laboratories

- **M. Lynn Crismon, Pharm.D.**, The University of Texas at Austin College of Pharmacy: **Project Co-Director**

Lynn Crismon, PharmD Research Support: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutica, Inc.; Pfizer Inc. Speakers Bureau: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Forest Laboratories, Inc.; Janssen Pharmaceutica, Inc.; Pharmacia Corporation; Pfizer Inc. Consultant: Merck-Medco Managed Care, LLC. Janssen Pharmaceutica, Inc.; Pharmacia Corporation; Pfizer Inc.; Eli Lilly and Company; Magellan Behavioral Healthcare, Inc.; Bristol-Myers Squibb Company  
[http://www.mesinc.com/education/monographs2/panic\\_disorder/disclosure.html](http://www.mesinc.com/education/monographs2/panic_disorder/disclosure.html)

- **Marcia Toprac, Ph.D.**, Deputy Medical Director for Research and Academic Collaboration, TXMHMR: **Project Co-Director**

MarciaToprac

<http://www.nimh.nih.gov/ncdeu/abstracts2003/ncdeu2018.cfm>

Poster Session II - 18Service Utilization Among Patients with Bipolar Disorder in the Texas Medication Algorithm Project Source of Funding: TMAP was funded by..... United States Pharmacopoeia Convention, Inc.....Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Company, Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Organon, Pfizer, Inc. and Wyeth-Ayerst Laboratories.

<http://www.mhmr.state.tx.us/centraloffice/medicaldirector/timaMDDman.pdf>

[PDF] TEXAS IMPLEMENTATION OF MEDICATION ALGORITHMS (TIMA) Guidelines ...File Format: PDF/Adobe Acrobat - View as HTML... were provided by Abbott Laboratories, Bristol-Myers Squibb Company, Eli Lilly and Company ... M. Lynn Crismon, PharmD. Tawny Bettinger, PharmD. Marcia Toprac, Ph.D ...  
[www.mhmr.state.tx.us/centraloffice/medicaldirector/timaMDDman.pdf](http://www.mhmr.state.tx.us/centraloffice/medicaldirector/timaMDDman.pdf) –

- **Alexander Miller, M.D.**, University of Texas Health Science Center at San Antonio: **Schizophrenia Module Director**

Dr. Miller has served as a consultant to leading pharmaceutical companies including AstraZeneca, Eli Lilly, Janssen and Pfizer, and is a frequent lecturer at medical symposia and conferences.

[http://biz.yahoo.com/bw/040628/285422\\_1.html](http://biz.yahoo.com/bw/040628/285422_1.html)

Dr. Miller has received grants from numerous drug companies:

<http://www.uthscsa.edu/opa/issues/new34-7/grants.html>

<http://www.uthscsa.edu/opa/issues/new32-33.html>

- **Madhukar Trivedi, M.D.**, The University of Texas Southwestern Medical Center - Dallas: **Major Depressive Disorder Module Director**

Dr. Trivedi has received research grants from Abbott, Akzo (Organon), Bayer, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Glaxo Wellcome, Janssen, Johnson & Johnson, MeadJohnson, Parke-Davis, Pfizer, Pharmacia - Upjohn, Solvay, and Wyeth - Ayerst. He has been a member of speakers' bureaus sponsored by Bristol-Myers Squibb, Forest Laboratories, Pharmacia - Upjohn, Solvay, and Wyeth Ayerst.

<http://home.cwru.edu/activism/READ/NEJM051800.html>

- **Patricia Suppes, M.D.,Ph.D.**, The University of Texas Southwestern Medical Center - Dallas: **Bipolar Disorder Module Director**

Suppes is a paid speaker for a number of drug companies:

<http://pn.psychiatryonline.org/cgi/content/full/37/4/9>

<http://www.psych.org/pnews/00-02-18/wednesday.html>

<http://www.ingenta.com/isis/searching/Expand/ingenta?pub=infobike://mksg/bdi/2004/0000006/00000003/art00005>

As Bipolar module director she receives funding from:

Robert Woods Johnson Foundation, Abbot Laboratories, Bristol Meyers Squibb, Eli Lilly, Forest Laboratories. GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Pfizer, U.S. Pharmacopeia and Wyeth Ayerst.

[https://labs-sec.uhs-sa.com/clinical\\_ext/RefDocs/TIMABipolar.pdf](https://labs-sec.uhs-sa.com/clinical_ext/RefDocs/TIMABipolar.pdf)

- **Steven P. Shon, M.D.**, Medical Director TXMHMR: **Project Co-Director**

Dr. Shon is a state employee and cannot accept remuneration in the forms accepted by the members above. However, a New York Times article By Melody Petersen, “*Making the Drugs, Shaping the rules*” Feb 1, 2004, reports Shon accepting money for doing

presentations on TMAP. This money was provided by Janssen Pharmaceutica to third parties, who passed the money on to Shon.

In addition to the Directors and Co-Directors above, other Texas University doctors have participated heavily in the development of the program. They include:

**Graham J. Emslie, M.D.**, Professor and Chair, Division of Child and Adolescent Psychiatry, University of Texas Southwestern Medical Center and Director, Bob Smith Center for Research in Pediatric Psychiatry, Dallas, TX. Consultant and member of speaker's bureaus for Bristol-Myers Squibb, Eli Lilly, McNeil, Otsuka, and Wyeth-Ayerst. Receives grant/research support from Novartis. (Preliminary Report of the Task Force on SSRIs and Suicidal Behavior in Youth, American College of Neuropsychopharmacology, January 21, 2004, p.16; On file with CSPI) Consultant to GlaxoSmithKline, Forest, and Pfizer. Receives research support from Eli Lilly, Organon, RepliGen, and Wyeth-Ayerst. Member of the speaker's bureau for McNeil. ("Experience in the use of SSRIs and other antidepressants in children and teens": conference disclosure notes: Child & Adolescent Psychiatry, convened by The College of Physicians and Surgeons of Columbia University, April 2003, Washington, DC. On file at CSPI) Serves on the Corporate Contributions and Research Committee for the American Academy of Child and Adolescent Psychiatry. (<http://www3.utsouthwestern.edu/psychiatry/facbios/emslie.htm>; accessed 6/16/03) <http://www.cspinet.org/cgi-bin/integrity.cgi>

### **Toprac, Marcia**

#### **Marcia Toprac**

<http://www.nimh.nih.gov/ncdeu/abstracts2003/ncdeu2018.cfm>

Poster Session II - 18 Service Utilization Among Patients with Bipolar Disorder in the Texas Medication Algorithm Project Source of Funding: TMAP was funded by..... United States Pharmacopoeia Convention, Inc..... Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Company, Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Organon, Pfizer, Inc. and Wyeth-Ayerst Laboratories.

<http://www.mhmr.state.tx.us/centraloffice/medicaldirector/timaMDDman.pdf>

[PDF] TEXAS IMPLEMENTATION OF MEDICATION ALGORITHMS (TIMA) Guidelines ... File Format: PDF/Adobe Acrobat - View as HTML... were provided by Abbott Laboratories, Bristol-Myers Squibb Company, Eli Lilly and Company ... M. Lynn Crismon, PharmD. Tawny Bettinger, PharmD. Marcia Toprac, Ph.D ... [www.mhmr.state.tx.us/centraloffice/medicaldirector/timaMDDman.pdf](http://www.mhmr.state.tx.us/centraloffice/medicaldirector/timaMDDman.pdf) –

**Karen Dineen Wagner, M.D., Ph.D.**, Director, Professor, and Vice Chair, Department of Psychiatry and Behavioral Sciences, Division of Child and Adolescent Psychiatry, University of Texas Medical Branch, Galveston, TX. Consultant to Wyeth-Ayerst. Member of the speaker's bureau for Janssen. Member of the scientific advisory board for Abbott Laboratories, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Novartis, Otsuka, Janssen, Pfizer, UCB Pharma, and Wyeth-Ayerst. (Preliminary Report of the Task Force on SSRIs and Suicidal Behavior in Youth, American College of Neuropsychopharmacology, January 21, 2004, p.16; On file with CSPI) Receives

research support from Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Novartis, Otsuka, Janssen, Pfizer, and UCB Pharma. GlaxoSmithKline, Organon, Pfizer, and Wyeth-Ayerst. Served as a National Institute of Mental Health consultant to Abbott Laboratories, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Member of the speaker's bureaus for Abbott Laboratories, Eli Lilly, GlaxoSmithKline, Forest Laboratories, Pfizer, and Novartis. (JAMA 2003; 290:1033-41)

<http://www.cspinet.org/cgi-bin/integrity.cgi>